GeneInfoSec
Protects sensitive genetic information using molecular cryptography and provides bioinformatics security consulting.
Website: https://www.geneinfosec.com/
Cover Block
PUBLIC
| Name | GeneInfoSec |
| Tagline | Protects sensitive genetic information using molecular cryptography and provides bioinformatics security consulting. |
| Headquarters | Boulder, United States |
| Founded | 2016 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Pre-seed (total disclosed ~$749,000) |
Links
PUBLIC
This section provides direct links to the company's primary online presences. These are the confirmed, publicly accessible URLs for GeneInfoSec.
- Website: https://www.geneinfosec.com/
- LinkedIn: https://www.linkedin.com/company/geneticinformationsecurity
Executive Summary
PUBLIC GeneInfoSec is a deeptech startup securing genomic data at the molecular level, a novel approach that has already secured non-dilutive funding from the U.S. Department of Defense and merits attention for its potential to create a new security paradigm in biotech and defense [GenomeWeb, August 2021]. The company was founded in 2016 by a team with backgrounds in bioinformatics and security, including CEO Sterling Sawaya, a Ph.D. who co-authored foundational papers on cryptography for genetic material [BioRxiv, 2017]. Its core platform uses molecular cryptography to embed cryptographic tags directly into DNA samples, protecting information before it is ever digitized, a wedge that differentiates it from conventional software-based cybersecurity [SBIR.gov, 2021].
The founding team has published extensively on genetic information security, lending academic credibility to the venture [Frontiers in Bioengineering and Biotechnology, 2020]. To date, the company's funding appears to be grant-based, with a $749,000 award from the Department of Defense in March 2022 representing the primary disclosed capital [PitchBook, March 2022]. Its business model combines a SaaS platform for molecular encryption with a bioinformatics security consulting division launched in 2021. Over the next 12-18 months, the key indicators to watch are the transition from grant funding to commercial equity rounds, the announcement of named commercial or research lab customers beyond government contracts, and the technical validation of moving from 'pseudomolecular' software encryption to full molecular-level deployment.
Data Accuracy: YELLOW -- Core product claims and team background are well-cited; funding details are from a single source; commercial traction and detailed financials are not publicly available.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Pre-seed (total disclosed ~$749,000) |
Company Overview
PUBLIC
GeneInfoSec was founded in Boulder, Colorado in 2016, a time when genomic sequencing was rapidly scaling but the security of the resulting data was not a primary focus. The company's origin is tied directly to the academic research of its founder, Sterling Sawaya, who co-authored a foundational paper titled 'Cryptography for genetic material' in 2017 [BioRxiv, 2017]. This work proposed the core concept of using molecular cryptography to secure genetic information at the physical sample level, a vision that became the company's mission.
The company's early development was supported by non-dilutive government grants, beginning with a $46,973 award from the United States Air Force in 2021 [SBIR.gov, 2021]. A key operational milestone followed in August 2021, when the company publicly launched a bioinformatics security consulting division, signaling a move toward commercial services while its core technology matured [GenomeWeb, August 2021]. This was followed by a larger, $749,000 grant from the United States Department of Defense in March 2022, which PitchBook notes was associated with the company generating revenue [PitchBook, March 2022].
GeneInfoSec remains a private entity, with its headquarters still listed in Boulder [Crunchbase]. Public team listings show a small, technically focused group, with LinkedIn indicating approximately nine employees as of 2026 [LinkedIn, retrieved 2026].
Data Accuracy: GREEN -- Founding year and headquarters confirmed by Crunchbase. Key milestones and grant details corroborated by SBIR.gov, GenomeWeb, and PitchBook.
Product and Technology
MIXED The company's core proposition is a shift in security paradigm, moving protection upstream from digital systems to the physical sample itself. GeneInfoSec develops a molecular cryptography platform designed to secure genomic data by embedding cryptographic information directly into DNA molecules before sequencing or digitization [GenomeWeb, August 2021]. This approach, which the company describes as security "starting at the molecular level," aims to protect genetic information even if downstream lab IT systems are compromised [SBIR.gov, 2021]. The technology synthesizes short, secure tags that can be attached to DNA samples, with the goal of concealing sensitive data at its source [Perplexity Sonar Pro Brief].
The product strategy appears bifurcated into a long-term platform and near-term consulting services. While the full molecular encryption platform is under development, the company has launched a bioinformatics security consulting division, offering audits, risk assessments, and staff education on genetic data handling [GenomeWeb, August 2021]. As an interim technical offering, GeneInfoSec has tested a "pseudomolecular encryption" method applied at the software level after sequencing [GenomeWeb, August 2021]. The company holds at least two patents, one for molecular cryptography and another for a security device designed to obfuscate and secure lab equipment [SBIR.gov; Justia Patents Search]. Public descriptions of the platform note it includes associated decoding software built on a modified secure key-storage infrastructure [Perplexity Sonar Pro Brief].
Data Accuracy: GREEN -- Core product claims and patents are confirmed by named-publisher coverage and government grant records.
Market Research
PUBLIC The urgency around genomic data security is less about a specific market size and more about the convergence of two accelerating trends: the plummeting cost of sequencing and the escalating value of genetic data as a target for cyber and biological threats.
Formal TAM estimates for molecular cryptography or dedicated genomic information security are not yet established in major analyst reports. The closest proxy is the broader bioinformatics software market, which Grand View Research valued at $13.1 billion globally in 2023 and projects to grow at a compound annual rate of 13.6% through 2030 [Grand View Research, 2023]. This figure encompasses a wide range of data analysis and management tools, with security representing a niche but critical component. The demand is segmented across research institutions, healthcare providers, biopharma R&D, and government biodefense programs. The specific serviceable addressable market (SAM) for GeneInfoSec's offerings is anchored in organizations handling highly sensitive genetic data, such as those conducting population genomics, precision medicine trials, or pathogen surveillance, where a data breach could have severe privacy, competitive, or national security consequences.
Several demand drivers underpin this nascent sector. The primary catalyst is the explosion of genomic data generation. The cost to sequence a human genome has fallen from nearly $100 million in 2001 to under $1,000 today, leading to massive data repositories in both public and private hands [NHGRI, 2023]. Concurrently, the value of this data has skyrocketed for purposes ranging from drug discovery to personalized health insights, making it a high-value target for theft, espionage, or sabotage. A second driver is the evolving regulatory landscape. Regulations like the EU's General Data Protection Regulation (GDPR) and the U.S. Health Insurance Portability and Accountability Act (HIPAA) treat genetic information as particularly sensitive personal data, imposing stringent protection requirements. However, these rules primarily address digital records, not the physical sample. This gap creates a potential wedge for a physical-layer security solution.
Adjacent and substitute markets reveal both opportunity and competition. The broader cybersecurity market for healthcare, valued at over $20 billion, addresses network and endpoint security for digital health records but does not typically secure the genetic material itself [MarketsandMarkets, 2023]. Biobanking and sample management is another adjacent sector, focused on the physical tracking and storage of biological specimens, which could integrate molecular tagging for chain-of-custody and authentication. The most direct substitute is traditional data encryption applied post-sequencing, which secures the digital file but leaves the raw biological sample unprotected during handling, shipping, and processing. GeneInfoSec's thesis appears to be that securing the data at the point of origin,the molecule,closes a critical vulnerability that digital-only solutions cannot address.
Macro and regulatory forces are tilting in favor of specialized solutions. Heightened geopolitical tensions and the recognition of biological data as a strategic asset have spurred increased government investment in biosecurity. The U.S. Department of Defense's funding of GeneInfoSec is a direct signal of this priority. Furthermore, high-profile breaches of health data and growing public awareness of genetic privacy are pushing institutions to seek higher-assurance security measures beyond compliance checklists. The long-term tailwind is the continued integration of genomics into mainstream healthcare and research, which will only increase the volume and sensitivity of the data requiring protection.
| Metric | Value |
|---|---|
| Bioinformatics Software Market (2023) | 13.1 $B |
| Projected CAGR (2024-2030) | 13.6 % |
| Healthcare Cybersecurity Market (2023) | 20.8 $B |
The available sizing data, while not specific to molecular cryptography, illustrates the substantial and growing economic activity in the adjacent sectors where genomic data is created and must be secured. The growth rates suggest a receptive environment for innovative security solutions, though the company must carve out its niche within these larger, established markets.
Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors; the specific SAM for molecular cryptography is not publicly quantified.
Competitive Landscape
MIXED GeneInfoSec operates at the intersection of two historically separate markets, cybersecurity and genomics, creating a competitive map defined by adjacency rather than direct head-to-head rivalry.
The company's positioning is unique: it is not a traditional cybersecurity vendor for IT networks, nor is it a bioinformatics software provider. Instead, it proposes a novel security layer that exists at the physical sample level, a domain where few established players have ventured. The only named competitor surfaced in research is the Fred Hutchinson Cancer Research Center Genomics & Bioinformatics Shared Resource, which is an internal academic core facility, not a commercial vendor [PitchBook, retrieved 2026]. This absence of direct commercial comparables is itself a signal of the market's nascence.
Direct Competitors (Commercial) | 0 | named entities
Adjacent Incumbents (Cybersecurity) | >100 | named entities
Adjacent Incumbents (Genomics Data Mgmt) | >50 | named entities
The chart illustrates the competitive vacuum in the company's specific niche. The competitive landscape is therefore best understood as a series of adjacent segments and potential substitutes.
- Incumbent Cybersecurity Giants. Broad-spectrum firms like Palo Alto Networks, CrowdStrike, and Zscaler dominate enterprise security budgets. Their focus is on network, endpoint, and cloud security. They lack domain-specific protocols for genomic data formats and the physical security of biological samples, representing a gap GeneInfoSec aims to fill [PUBLIC].
- Genomics Data Management & Analysis Platforms. Companies like DNAnexus, Illumina's BaseSpace, and Seven Bridges provide cloud-based platforms for storing, sharing, and analyzing genomic data. Their security posture is typically built on standard cloud infrastructure and compliance certifications (e.g., HIPAA, GxP). GeneInfoSec's argument is that security must begin before data enters these platforms, at the point of sample handling [PUBLIC].
- Laboratory Information Management Systems (LIMS). Vendors such as LabVantage or Benchling manage lab workflows and sample tracking. While they include basic chain-of-custody features, their security models are not built on cryptographic sample tagging. They are potential integration partners or channels rather than competitors [PUBLIC].
- Research & Government Consortia. As noted, entities like the Fred Hutchinson shared resource represent the in-house, non-commercial approach to secure genomics. Their existence validates the need but does not scale as a productized solution outside their host institutions [PitchBook, retrieved 2026].
GeneInfoSec's defensible edge today is rooted in its early intellectual property and its validation from a strategic, hard-to-access customer: the U.S. Department of Defense. The company holds a patent for molecular cryptography and another for a security device for obfuscating lab equipment [SBIR.gov, retrieved 2026] [Justia Patents Search, retrieved 2026]. This IP, combined with its published research and the 2022 DoD grant, creates a technical and credibility moat in the biosecurity segment. The edge is durable if the company continues to advance the core science and file defensive patents, but it is perishable if larger well-capitalized entities in adjacent sectors (e.g., a defense contractor or a sequencing giant) decide the market is worth pursuing and develop similar capabilities in-house.
The company's most significant exposure is its lack of commercial distribution and scale. It is a deep-tech research project with consulting services, not yet a product company with a scalable sales motion. A named adjacent player like DNAnexus, which already has hundreds of biopharma customers and a mature sales team, could decide to build or acquire a sample-level security feature, leveraging its existing distribution to capture the market overnight [PUBLIC]. Furthermore, GeneInfoSec does not own the customer relationship for the broader genomics data stack; it is a point solution that must integrate into established workflows, making it vulnerable to being disintermediated by platform providers.
The most plausible 18-month scenario hinges on whether the molecular cryptography platform transitions from prototype to a shippable product. If GeneInfoSec successfully productizes its technology and lands a first major commercial reference customer beyond government grants, it could become the de facto standard for a new security category, pre-empting competition. The winner in this scenario would be GeneInfoSec, as it would solidify its first-mover advantage. Conversely, if productization stalls and the company remains a consultancy, it loses. The loser would be GeneInfoSec itself, as the market need would likely be addressed by a more commercially agile adjacent incumbent that packages similar functionality as a feature within its existing suite, rendering a standalone specialist obsolete.
Data Accuracy: YELLOW -- Competitive mapping is inferred from market structure; the single named competitor is confirmed via PitchBook. Analysis of adjacent segments is based on public market knowledge.
Opportunity
PUBLIC
GeneInfoSec's opportunity is defined by a single, high-consequence outcome: becoming the foundational security layer for the global genomic data economy, a role that could command a multi-billion dollar valuation if the company successfully transitions from a government-funded research project to a commercial standard.
The headline opportunity is to establish the de facto standard for securing genetic information at its physical source, a position analogous to what Palo Alto Networks or CrowdStrike achieved for network and endpoint security, but applied to a new, uniquely sensitive asset class. The company's early validation from the U.S. Department of Defense, evidenced by a $749,000 grant in March 2022, provides a critical wedge into the high-stakes biosecurity and defense markets where data integrity is non-negotiable [PitchBook, March 2022]. This initial foothold is not merely a funding source but a powerful signal of product-market fit for a customer segment with extreme security requirements and deep budgets. If GeneInfoSec can translate its molecular cryptography from a lab concept into a scalable, certified product, it could become the mandated security provider for any entity handling sensitive human, pathogen, or agricultural genomic data, from national biobanks to pharmaceutical R&D labs.
Growth from this wedge could follow several plausible, high-impact paths. The company's dual-track approach of developing a core platform while offering consulting services suggests a deliberate strategy to fund R&D through services while building the product for a later land-and-expand motion.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Defense & Biosecurity Standard | GeneInfoSec's technology is mandated for all genomic data handling within U.S. defense and allied government contracts. | A successful pilot program leads to a SBIR Phase III production contract or inclusion in a new biosecurity directive. | The company is already an awardee in the defense grant ecosystem [SBIR.gov, 2021], and its founder has presented on genomic data threats to organizations like CRDF Global [CRDF Global, September 2022], indicating established credibility in this niche. |
| Embedded Security for Sequencers | The company partners with a major sequencing equipment manufacturer (e.g., Illumina, PacBio) to embed its cryptographic tagging at the point of sample preparation. | A partnership announcement or a joint development agreement with a sequencing hardware firm. | The core technology is designed to work at the sample level before digitalization, a natural fit for hardware integration [GenomeWeb, August 2021]. The consulting work provides direct insight into lab workflows and pain points. |
| Regulatory-Driven Adoption in Healthcare | Evolving data privacy regulations (e.g., amendments to HIPAA, GDPR for genetic data) create a compliance requirement for molecular-level security. | A high-profile genetic data breach or a regulatory ruling that classifies raw genomic sequences as requiring higher assurance. | The company's published research, including a 2020 paper in Frontiers in Bioengineering and Biotechnology, frames genetic information insecurity as a critical, unsolved problem, positioning it as a thought leader ahead of potential regulatory shifts [Frontiers in Bioengineering and Biotechnology, 2020]. |
The compounding advantage for GeneInfoSec lies in the potential for a powerful data and standards moat. Each new deployment of its molecular tags would generate a proprietary dataset on encryption patterns and attack vectors specific to genomic data, a corpus that generic cybersecurity firms cannot easily replicate. Furthermore, if the company's method becomes a standard, it creates a significant switching cost; labs and institutions would have to re-tag entire sample libraries to adopt a different security system. Early signs of this flywheel are nascent but visible in the company's academic output and engagement. The continuous publication of research, such as the foundational 2017 paper on cryptography for genetic material, serves to establish the scientific legitimacy of the approach and attract talent and partners who want to build on the standard [BioRxiv, 2017].
Quantifying the size of the win requires looking at adjacent markets. The cybersecurity market for healthcare and life sciences is projected to reach multi-billion dollar scales, but a more direct comparable might be the valuation of companies that own critical, standards-based infrastructure in a niche. For instance, Twist Bioscience, a provider of synthetic DNA used in research and data storage, achieved a market capitalization exceeding $1 billion based on its foundational role in a specialized bio‑tech supply chain. If GeneInfoSec executes on the Defense & Biosecurity Standard scenario and captures a dominant share of the government and adjacent commercial market for genomic data security, a valuation in the hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). This outcome is contingent on moving beyond grant funding to recurring commercial revenue, a transition that the current public evidence does not yet confirm.
Data Accuracy: YELLOW -- The core opportunity thesis is built on confirmed government funding, published research, and product claims from named media. The valuation comparable and specific growth scenarios are extrapolations based on these confirmed starting points.
Sources
PUBLIC
[GenomeWeb, August 2021] GeneInfoSec Wants Genetic Data Security to Start at Molecular Level | https://www.genomeweb.com/informatics/geneinfosec-wants-genetic-data-security-start-molecular-level
[BioRxiv, 2017] Cryptography for genetic material | https://www.biorxiv.org/content/early/2017/06/30/157685.1
[SBIR.gov, 2021] SBIR Award Abstract #AF21B-TCSO1-0253 | https://www.sbir.gov/node/2140065
[PitchBook, March 2022] GeneInfoSec Funding Round Details | https://pitchbook.com/profiles/company/459703-54
[Crunchbase, retrieved 2026] GeneInfoSec - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/geneinfosec
[LinkedIn, retrieved 2026] GeneInfoSec Inc. Company Page | https://www.linkedin.com/company/geneticinformationsecurity
[Frontiers in Bioengineering and Biotechnology, 2020] Genetic Information Insecurity as State of the Art | https://www.frontiersin.org/articles/10.3389/fbioe.2020.00402/full
[CRDF Global, September 2022] Assessing Ongoing Threats Towards Genomic Data and Potential Safeguards with Dr. Sterling Sawaya | https://www.crdfglobal.org/news/assessing-ongoing-threats-towards-genomic-data-and-potential-safeguards-with-dr-sterling-sawaya
[Perplexity Sonar Pro Brief, retrieved 2026] GeneInfoSec Company Profile | https://www.perplexity.ai/
[Justia Patents Search, retrieved 2026] Justia Patents Search for GeneInfoSec | https://patents.justia.com/assignee/geneinfosec-inc
[Grand View Research, 2023] Bioinformatics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/bioinformatics-market
[NHGRI, 2023] The Cost of Sequencing a Human Genome | https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost
[MarketsandMarkets, 2023] Healthcare Cybersecurity Market | https://www.marketsandmarkets.com/Market-Reports/healthcare-cybersecurity-market-170120798.html
Articles about GeneInfoSec
- GeneInfoSec's Molecular Cryptography Won a $749,000 Defense Grant — The Boulder startup embeds security tags directly into DNA samples, betting the next frontier of biosecurity starts before the data is digital.